Cite
HARVARD Citation
Möbus, V. et al. (2018). Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. Annals of oncology. pp. 178-185. [Online].